[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1984

Meclofenamate for Psoriasis

Author Affiliations

Department of Dermatology North Carolina Memorial Hospital Chapel Hill, NC 27514

Northwestern University Medical Center Chicago

Arch Dermatol. 1984;120(4):438. doi:10.1001/archderm.1984.01650400020006
Abstract

To the Editor.—  Meclofenamate sodium (Meclomen) is a nonsteroidal anti-inflammatory agent that has been used for the treatment of rheumatoid arthritis and osteoarthritis.1 Its mechanism of action is believed to be the inhibition of prostaglandin synthesis. The drug causes diarrhea in up to one third of the treated patients, but its other side effects, eg, abdominal discomfort, anemia, and rashes, are rare.The potential efficacy of meclofenamate in psoriasis was suggested by Winthrop,2 who found notable regression of psoriasis within one week after he and two patients began using the drug for psoriatic arthritis. Other inhibitors of prostaglandin synthesis, tolmetin sodium3 and benoxaprofen,4 have been described as effective for psoriasis.

Patients and Methods.—  We performed a double-blind randomized trial of 15 patients with psoriasis alone or with psoriasis and arthritis. Patients were required to stop any systemic or topical antipsoriatic agents and phototherapy for two weeks

First Page Preview View Large
First page PDF preview
First page PDF preview
×